Recordati SpA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IT0003828271
EUR
48.20
0.12 (0.25%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

194.84 k

Shareholding (Dec 2023)

FII

0.01%

Held by 2 FIIs

DII

99.99%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Operating profit has grown by an annual rate 6.94% of over the last 5 years

 
2

With ROE of 23.07%, it has a Very Expensive valuation with a 5.79 Price to Book Value

3

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 9,883 Million ()

stock-summary
P/E

25.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

22.92%

stock-summary
Debt Equity

0.86

stock-summary
Return on Equity

22.64%

stock-summary
Price to Book

5.13

Revenue and Profits:
Net Sales:
644 Million
(Quarterly Results - Jun 2025)
Net Profit:
91 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.58%
0%
-10.58%
6 Months
-12.84%
0%
-12.84%
1 Year
-5.86%
0%
-5.86%
2 Years
2.08%
0%
2.08%
3 Years
15.06%
0%
15.06%
4 Years
-10.01%
0%
-10.01%
5 Years
9.5%
0%
9.5%

Recordati SpA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
11.61%
EBIT Growth (5y)
6.94%
EBIT to Interest (avg)
16.62
Debt to EBITDA (avg)
1.95
Net Debt to Equity (avg)
1.01
Sales to Capital Employed (avg)
0.58
Tax Ratio
24.13%
Dividend Payout Ratio
62.91%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
19.37%
ROE (avg)
25.39%
Valuation key factors
Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
5.79
EV to EBIT
19.40
EV to EBITDA
15.12
EV to Capital Employed
3.26
EV to Sales
5.21
PEG Ratio
2.92
Dividend Yield
20.45%
ROCE (Latest)
16.80%
ROE (Latest)
23.07%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 2 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -5.31% vs 13.62% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -27.12% vs 60.05% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "643.90",
          "val2": "680.00",
          "chgp": "-5.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "200.60",
          "val2": "248.20",
          "chgp": "-19.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "24.40",
          "val2": "26.40",
          "chgp": "-7.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-15.70",
          "val2": "-1.10",
          "chgp": "-1,327.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "91.10",
          "val2": "125.00",
          "chgp": "-27.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "232.80%",
          "val2": "290.10%",
          "chgp": "-5.73%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 12.45% vs 12.36% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 7.01% vs 24.62% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,341.60",
          "val2": "2,082.30",
          "chgp": "12.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "826.90",
          "val2": "708.40",
          "chgp": "16.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "81.20",
          "val2": "74.50",
          "chgp": "8.99%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-22.40",
          "val2": "-10.00",
          "chgp": "-124.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "416.50",
          "val2": "389.20",
          "chgp": "7.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "281.80%",
          "val2": "271.70%",
          "chgp": "1.01%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
643.90
680.00
-5.31%
Operating Profit (PBDIT) excl Other Income
200.60
248.20
-19.18%
Interest
24.40
26.40
-7.58%
Exceptional Items
-15.70
-1.10
-1,327.27%
Consolidate Net Profit
91.10
125.00
-27.12%
Operating Profit Margin (Excl OI)
232.80%
290.10%
-5.73%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -5.31% vs 13.62% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -27.12% vs 60.05% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
2,341.60
2,082.30
12.45%
Operating Profit (PBDIT) excl Other Income
826.90
708.40
16.73%
Interest
81.20
74.50
8.99%
Exceptional Items
-22.40
-10.00
-124.00%
Consolidate Net Profit
416.50
389.20
7.01%
Operating Profit Margin (Excl OI)
281.80%
271.70%
1.01%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 12.45% vs 12.36% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 7.01% vs 24.62% in Dec 2023

stock-summaryCompany CV
About Recordati SpA stock-summary
stock-summary
Recordati SpA
Pharmaceuticals & Biotechnology
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.
Company Coordinates stock-summary
Company Details
Via M. Civitali, 1 , MILANO None : 20148
stock-summary
Tel: 39 02 48787139 02 48787393
stock-summary
Registrar Details